AdaptHealth (NASDAQ:AHCO) Major Shareholder Buys $6,707,239.28 in Stock

AdaptHealth Corp. (NASDAQ:AHCO) major shareholder Richard Cashin, Jr. bought 689,336 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were acquired at an average price of $9.73 per share, with a total value of $6,707,239.28. Following the completion of the transaction, the insider owned 15,864,871 shares of the company’s stock, valued at approximately $154,365,194.83. The trade was a 4.54% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

AdaptHealth Stock Up 8.7%

Shares of AHCO opened at $10.60 on Friday. The firm has a fifty day moving average price of $10.10 and a 200-day moving average price of $9.68. The company has a current ratio of 1.02, a quick ratio of 0.81 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $1.44 billion, a P/E ratio of -19.27, a P/E/G ratio of 1.22 and a beta of 1.76. AdaptHealth Corp. has a 12-month low of $7.11 and a 12-month high of $11.17.

AdaptHealth (NASDAQ:AHCO) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of $0.34 by ($1.10). AdaptHealth had a positive return on equity of 3.42% and a negative net margin of 2.18%.The company had revenue of $846.29 million during the quarter, compared to analysts’ expectations of $832.51 million. During the same period in the prior year, the business earned $0.34 EPS. The company’s quarterly revenue was down 1.2% on a year-over-year basis. Equities research analysts expect that AdaptHealth Corp. will post 0.88 earnings per share for the current year.

AdaptHealth News Summary

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Major shareholder Richard M. Cashin Jr. executed multiple buys over March 10–12 totaling roughly 2.05 million shares (~$19.9M) at about $9.73/share, lifting his stake to ~15.86M shares — a strong insider vote of confidence that likely supported the rally. Investing.com article
• Positive Sentiment: Other filings and coverage show the same insider purchases (disclosed to the SEC) and note a multi-day, material increase in Cashin’s position — reinforcing the market interpretation of the buy as strategic accumulation rather than one-off trading. InsiderTrades article
• Positive Sentiment: Institutional activity shows selective buying (e.g., Goldman Sachs, UBS, new position from Woodline), which can add buying pressure and liquidity support. MarketBeat institutional note
• Neutral Sentiment: Analyst coverage is mixed — several “outperform”/buy ratings and raises to price targets offset by some downgrades and cuts; consensus is a moderate-buy with an average target ~ $13.25, so analyst views provide both support and caution. MarketBeat analyst summary
• Neutral Sentiment: Valuation write-ups are assessing the stock after recent weakness — useful for longer-term context but not an immediate catalyst. Yahoo Finance article
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent (shows 0 shares/NaN increases), so don’t read too much into those numbers until corrected filings are available.
• Negative Sentiment: Recent quarterly results (Feb. 24) included a large EPS miss (reported -$0.76 vs. consensus $0.34) and slight revenue decline year-over-year — fundamental weakness that has pressured valuation and explains earlier share-price weakness. SEC / MarketBeat filing

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AHCO. Wall Street Zen downgraded shares of AdaptHealth from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Zacks Research upgraded AdaptHealth from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Leerink Partners decreased their target price on AdaptHealth from $13.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Weiss Ratings cut AdaptHealth from a “hold (c-)” rating to a “sell (d)” rating in a report on Wednesday, February 25th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $13.00 price target on shares of AdaptHealth in a research report on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.25.

Hedge Funds Weigh In On AdaptHealth

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Exchange Traded Concepts LLC purchased a new stake in AdaptHealth during the third quarter worth $1,171,000. Prospera Financial Services Inc increased its holdings in shares of AdaptHealth by 75.2% in the 2nd quarter. Prospera Financial Services Inc now owns 43,287 shares of the company’s stock valued at $408,000 after acquiring an additional 18,586 shares during the period. Bastion Asset Management Inc. purchased a new position in shares of AdaptHealth in the 3rd quarter valued at $4,199,000. LSV Asset Management bought a new position in shares of AdaptHealth in the 2nd quarter worth $448,000. Finally, Bailard Inc. raised its position in shares of AdaptHealth by 41.6% in the 2nd quarter. Bailard Inc. now owns 42,058 shares of the company’s stock worth $397,000 after acquiring an additional 12,358 shares in the last quarter. 82.67% of the stock is currently owned by institutional investors.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.